MBX Biosciences, Inc.
For the period ended Mar 31, 2026. Filed May 7, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 7, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
Item 5. Other Information.
(c) During thethree months ended March 31, 2026, none of our directors or “officers,” as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934, adopted orterminated a Rule 10b5-1 trading plan or arrangement or a non-Rule 10b5-1 trading plan or arrangement, as defined in Item 408(c) of Regulation S-K, except as follows:
| Name | Title | Reporting Action | Plan Start Date | Plan End Date | Maximum number of Shares of Common Stock to be Sold | Intended to Satisfy Rule 10b5-1(c)? |
|---|---|---|---|---|---|---|
| Salomon Azoulay | Chief Medical Officer | Plan Adoption | January 27, 2026 | June 30, 2026 | 70,003 | Yes |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.